Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Journal of Cellular Physiology|December 15, 2006
Fas ligand expression in TM4 Sertoli cells is enhanced by estradiol "in situ" productionStefania Catalano, Pietro Rizza, Guowei Gu, et al.
Acta Pharmaceutica Sinica. B|February 23, 2023
Late-stage cascade of oxidation reactions during the biosynthesis of oxalicine B in <i>Penicillium oxalicum</i>Tao Zhang, Guowei Gu, Guodong Liu, et al.
Water Research X|October 21, 2024
Start-up of a full-scale two-stage partial nitritation/anammox (PN/A) process treating reject water from high solid anaerobic sludge digestion (HSAD)Shuyan Zhou, Hui Gong, Enhui Xu, et al.
Journal of Cellular Physiology|November 7, 2008
Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferationStefania Catalano, Cinzia Giordano, Pietro Rizza, et al.
Blood Advances|March 1, 2023
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysisAshley Aaroe, Razelle Kurzrock, Gaurav Goyal, et al.
Cell Communication and Signaling : CCS|June 3, 2025
Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancerAmanda Caruso, Felice Maria Accattatis, Cinzia Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast CancerFoluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Pageof 10